<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218357</url>
  </required_header>
  <id_info>
    <org_study_id>1908002524</org_study_id>
    <nct_id>NCT04218357</nct_id>
  </id_info>
  <brief_title>Probenecid as Medication for Alcohol Use Disorder</brief_title>
  <acronym>PROB</acronym>
  <official_title>Probenecid as Pharmacotherapy for Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design is a randomized, within-subject, crossover, double-blind, placebo-controlled human
      alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two
      laboratory sessions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a total of four study visits. Visit 1 is the screening for eligibility (medical
      and physical examination). On Visits 2 and 3, participants will undergo an alcohol laboratory
      session with a one week washout period before administering the alternate therapy. The study
      will conclude at Visit 4.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2, 2020</start_date>
  <completion_date type="Anticipated">February 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stimulant effects of alcohol when co-administered with drug or matching placebo</measure>
    <time_frame>Change from Day 3 to day 10 of the trial</time_frame>
    <description>assessed using the change in the Biphasic Alcohol Effects Scale (BAES), scale 0-10 (direct and reverse score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedative effects of alcohol when co-administered with drug or matching placebo</measure>
    <time_frame>Change from Day 3 to day 10 of the trial</time_frame>
    <description>assessed using change in the Biphasic Alcohol Effects Scale (BAES), scale 0-10 (direct and reverse score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>Change from Day 3 to day 10 of the trial</time_frame>
    <description>assessed using change in the alcohol urge questionnaire (AUQ), scale 0-7 (7 worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Probenecid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g probenecid, one pill by mouth once, for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one pill by mouth once, for one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
    <description>safety</description>
    <arm_group_label>Probenecid</arm_group_label>
    <other_name>Probalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>matching placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 21-70 (inclusive) years; women &gt;7 drinks/week; men &gt;14 drinks/week;

          -  meet any DSM-5 criteria score for AUD;

          -  Breath alcohol Content (BrAC)=0.00 at each visit;

          -  In good health as confirmed by medical history, physical examination and lab tests;

          -  Willing to adhere to the study procedures;

          -  Understand informed consent and questionnaires in English at an 8th grade level

        Exclusion Criteria:

          -  Women who are breastfeeding or have a positive urine screen for pregnancy

          -  CrCl &lt; 60mL/min

          -  Taking aspirin (salicylates may reduce effect of probenecid)

          -  Taking penicillin

          -  Taking methotrexate (may increase concentration)

          -  Taking other medications that may interact with probenecid

          -  History of suicide attempts in the last three years

          -  Current diagnosis of another substance disorder(s) other than nicotine, as assessed by
             self-reports and urine toxicology screen at baseline

          -  History of hypersensitivity to sulfa drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina L Haass-koffler, PHARMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoe Brown, BA</last_name>
    <phone>401-863-6646</phone>
    <email>alcohol-stress-study@brown.edu</email>
  </overall_contact>
  <results_reference>
    <citation>Tunstall BJ, Lorrai I, McConnell SA, Gazo KL, Zallar LJ, de Guglielmo G, Hoang I, Haass-Koffler CL, Repunte-Canonigo V, Koob GF, Vendruscolo LF, Sanna PP. Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder? Alcohol Alcohol. 2019 Jan 9;54(5):497-502. doi: 10.1093/alcalc/agz054.</citation>
    <PMID>31535696</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Carolina Haass-Koffler</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

